evipedia.ai ← Back

Topical Naringenin for Hair Regrowth

Evidence Review created on 07/31/2026 using AI4L / Opus 4.8

Also known as: Naringenin, 4′,5,7-Trihydroxyflavanone, (2S)-Naringenin, 5,7,4′-Trihydroxyflavanone

Motivation

Naringenin is a natural plant compound found in citrus fruits such as grapefruit, oranges, and tomatoes, where it gives grapefruit part of its bitter taste. It has long been studied for its antioxidant and calming effects on inflamed tissue. More recently, researchers have begun applying it directly to the skin of the scalp to see whether it can slow hair loss and encourage new hair to grow, placing it alongside other plant extracts explored as gentler alternatives or add-ons to standard hair treatments.

Interest in naringenin for hair is very new and grew out of two observations: the compound appears to protect cells from stress-related damage, and in early animal work it raised a signal that helps grow the tiny blood vessels feeding hair roots. This overlaps with how well-known hair treatments work, drawing attention from people looking beyond conventional options.

This review examines what is currently known about applying naringenin to the scalp for hair regrowth. It gathers the available laboratory and animal findings, the proposed ways it might work, its likely benefits and risks, and the large gaps that remain because no human trials have yet tested it for this use.

Benefits - Risks - Protocol - Conclusion

This section collects high-level, directly relevant sources that give an overview of naringenin’s role in hair biology and its early testing for hair regrowth.

Only three directly relevant, high-quality sources were found; the list is intentionally not padded with marginally relevant material, and no content from the priority experts on naringenin for hair could be located.

Grokipedia

Naringenin

The Grokipedia article gives a broad, well-referenced overview of naringenin’s chemistry, dietary sources, low oral bioavailability, and its antioxidant and anti-inflammatory pharmacology, which is useful background even though it does not focus specifically on hair.

Examine

No Examine article exists for naringenin. Examine.com does not currently maintain a dedicated monograph for this citrus flavonoid.

ConsumerLab

No ConsumerLab article exists for naringenin. The site returned no product reviews, clinical updates, or answers covering this compound.

Systematic Reviews

This section lists systematic reviews and meta-analyses of naringenin; none address topical use for hair specifically, so those most relevant to its antioxidant and anti-inflammatory actions — the mechanisms proposed for hair — are prioritized.

Mechanism of Action

Naringenin is a flavanone, a subclass of plant flavonoids. Its proposed actions on hair are indirect and overlapping rather than tied to a single receptor.

The primary pathways described in the available research are:

  • Antioxidant defence. Naringenin neutralizes reactive oxygen species (ROS, unstable molecules that damage cells) and raises total antioxidant capacity (TAC, the overall ability of tissue to buffer oxidative damage). In the one animal study of topical use, treated skin showed higher tissue antioxidant capacity, which may protect the dermal papilla — the cluster of cells at the base of each follicle that directs hair growth — from stress-driven ageing.

  • Blood-vessel support. Naringenin raised vascular endothelial growth factor (VEGF), a signal that stimulates growth of the small blood vessels supplying the follicle. Better perfusion is associated with prolonging anagen (the active growth phase) and delaying entry into telogen (the resting phase).

  • Anti-inflammatory signalling. Naringenin suppresses nuclear factor kappa B (NF-κB, a master control switch that turns on inflammatory genes) and lowers inflammatory messengers such as tumour necrosis factor alpha and interleukin-6. Low-grade inflammation around the follicle is a recognised feature of androgenetic alopecia (AGA, common pattern hair loss), so damping it is a plausible route to benefit.

  • Growth-factor and pathway modulation. Broader reviews of plant compounds for hair describe up-regulation of growth factors such as insulin-like growth factor 1 (IGF-1), keratinocyte growth factor (KGF), and hepatocyte growth factor (HGF), and stimulation of the Wnt/β-catenin pathway (a cell-signalling cascade that drives follicle regeneration) while suppressing transforming growth factor beta signalling that pushes follicles into rest. Naringenin’s specific contribution to these steps is inferred from its flavonoid class rather than proven for hair.

  • Pigment support. Naringenin can raise the activity of tyrosinase (the rate-limiting enzyme for making hair pigment), a mechanism relevant to hair colour rather than density.

Competing interpretations exist. Supporters read the animal and cell data as evidence of a genuine follicle-stimulating effect. A sceptical reading holds that the observed changes (higher antioxidant capacity, higher VEGF) are generic tissue responses seen with many antioxidants and do not establish that naringenin regrows human hair; naringenin also engages the aryl hydrocarbon receptor (AhR, a sensor that alters skin-cell behaviour), whose net effect on the follicle is not established.

Key pharmacological properties: naringenin is a small lipophilic molecule (molecular weight about 272) with poor oral bioavailability (roughly 5–15%) but reasonable ability to cross the outer skin layer, which is why topical delivery is of interest; penetration is improved by ethanol, propylene glycol, or nanoemulsion vehicles. Its systemic elimination half-life after absorption is short (on the order of a few hours). It is not receptor-selective; its effects are pleiotropic (many targets at once). Metabolism is dominated by phase II conjugation via UGT and SULT (enzyme families that attach water-soluble tags to speed clearance), and naringenin also inhibits several drug-metabolizing enzymes including CYP3A4, CYP1A2, and CYP2C9 (major liver enzymes that break down many medications) — the basis of the classic “grapefruit effect.”

Historical Context & Evolution

Naringenin was first characterized as the aglycone (the sugar-free core) of naringin, the compound responsible for grapefruit’s bitterness, and for decades was studied mainly as a citrus food chemical and flavour component.

Its move into health research came through two doors. First, grapefruit-juice drug interactions in the 1990s drew attention to naringenin and related flavonoids as inhibitors of the CYP3A4 enzyme, prompting detailed study of its pharmacology. Second, as interest in dietary polyphenols grew, naringenin was investigated for antioxidant, anti-inflammatory, metabolic, and cardiovascular effects, almost entirely in cell and animal models.

The application to hair is recent, emerging in the 2020s from the wider search for plant flavonoids that might act as gentler alternatives or add-ons to established topical hair treatments. The reasoning was mechanistic: naringenin’s antioxidant, anti-inflammatory, and blood-vessel-supporting actions resemble the pathways that conventional hair treatments are thought to influence. A controlled mouse study then reported that topical naringenin increased hair growth, follicle diameter, and follicle number, and that combining it with minoxidil produced a larger effect than either alone. Those are the actual findings that put naringenin on the map for hair; they have not been dismissed, but neither have they been reproduced in humans. The current standing is best described as an early, mechanistically plausible hypothesis: the evolution of opinion so far is a move from “citrus food chemical” to “candidate topical agent,” with the decisive human evidence still absent on both sides.

Expected Benefits

High 🟩 🟩 🟩

No benefits currently meet this evidence threshold; there are no human clinical trials of topical naringenin for hair.

Medium 🟩 🟩

No benefits currently meet this evidence threshold.

Low 🟩

Promotion of Hair Regrowth and Anagen Support

The central claim is that applying naringenin to the scalp stimulates new hair growth and enlarges existing follicles. The proposed mechanism combines antioxidant protection of the dermal papilla, a rise in the blood-vessel signal VEGF, and reduced local inflammation. The evidence basis is one controlled mouse study reporting significantly greater hair growth, follicle diameter, and follicle count versus vehicle, supported by laboratory reviews describing flavonoid effects on follicle cells. For a proactive reader, the key limitation is that no human has been tested, so the effect size and real-world relevance are unknown.

Magnitude: Not quantified in available studies.

Additive Effect When Combined with Minoxidil

Rather than replacing standard topical treatment, naringenin may add to it. In the same animal study, a naringenin-plus-minoxidil combination outperformed either agent alone on hair growth, follicle diameter, tissue antioxidant capacity, and VEGF activity, consistent with the two agents acting through complementary routes. This positions naringenin as a possible add-on for someone already using minoxidil, though again the data are animal-only.

Magnitude: In the mouse study, the naringenin–minoxidil combination produced greater hair growth, follicle diameter, and follicle counts than either agent alone (effect sizes not numerically reported).

Speculative 🟨

Repigmentation of Greying Hair

Separate from regrowth, naringenin has been listed among plant compounds that raise the activity of the pigment-making enzyme tyrosinase and boost melanin production in pigment cells. This raises the possibility of modestly darkening greying hair. The basis is laboratory work on isolated cells and a narrative review only, with no animal or human hair-colour outcomes, so this remains a hypothesis.

Protection Against Androgen-Driven Follicle Miniaturization

Because some flavonoids weakly inhibit 5α-reductase (the enzyme that converts testosterone into dihydrotestosterone, or DHT, the hormone that shrinks scalp follicles), naringenin has been proposed to blunt the hormonal process behind pattern hair loss. There are no studies measuring naringenin’s effect on scalp DHT or follicle size in this context; the idea is extrapolated from its chemical class.

Benefit in Inflammatory Scalp Conditions

Given naringenin’s consistent anti-inflammatory signal in other tissues, it has been suggested it could calm the inflammation seen in some scalp and follicle disorders. This is supported only by indirect, non-scalp preclinical data and mechanistic reasoning, with no direct testing in inflammatory hair loss.

Benefit-Modifying Factors

  • Genetic factors: Variants in the androgen receptor and in 5α-reductase largely determine how aggressively pattern hair loss progresses, and could set a ceiling on any benefit from an antioxidant agent that does not strongly target the hormonal pathway. Differences in antioxidant-pathway genes may also influence responsiveness.

  • Baseline biomarker levels: People with higher baseline oxidative stress or low tissue antioxidant status may, in theory, gain more from an antioxidant compound; those with advanced follicle miniaturization have fewer viable follicles to recover and may benefit less.

  • Sex-based differences: Pattern hair loss differs by sex in distribution and hormonal drivers, so the balance of naringenin’s antioxidant versus hormonal relevance likely differs between men and women; no sex-specific data exist for this use.

  • Pre-existing health conditions: Untreated thyroid disease, iron deficiency, or protein malnutrition independently suppress hair growth and would blunt any topical effect until corrected.

  • Age-related considerations: Older follicles accumulate cellular senescence and respond less vigorously to growth stimuli, so those at the older end of the target range may see smaller effects even if the compound is active.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risks currently meet this evidence threshold.

Medium 🟥 🟥

No risks currently meet this evidence threshold.

Low 🟥

Application-Site Skin Irritation

The most likely adverse effect is local irritation — redness, itching, dryness, or stinging — at the site of application. This is driven as much by the vehicle (often ethanol or propylene glycol, used to help the compound penetrate) as by naringenin itself, which is generally well tolerated on skin. Irritation is usually mild and reversible on stopping, but broken or inflamed skin increases both discomfort and absorption.

Magnitude: Not quantified in available studies.

Speculative 🟨

Contact Allergy or Sensitization

As with many plant-derived topicals, repeated exposure could in principle provoke an allergic contact reaction in susceptible individuals. No cases have been documented for naringenin specifically, so this is a class-based caution rather than a demonstrated risk.

Hormonal Effects from Systemic Exposure

Naringenin is a weak phytoestrogen (it can bind the estrogen receptor, ER, at high concentrations). With scalp-only application, systemic absorption is expected to be minimal, but heavy use over large areas has not been studied, leaving a theoretical concern for people with hormone-sensitive conditions.

Interference with Drug Metabolism

If enough naringenin were absorbed, its inhibition of enzymes such as CYP3A4 and of drug transporters could raise blood levels of some medications — the same mechanism behind grapefruit-drug interactions. Topical scalp doses make meaningful systemic inhibition unlikely, but the threshold has not been defined.

Unknown Long-Term Topical Safety

Because no human has been followed on topical naringenin for hair, effects of months-to-years of daily scalp use — on the skin barrier, follicles, or hormone-sensitive tissue — are simply unknown. This uncertainty is itself a risk for anyone adopting it.

Risk-Modifying Factors

  • Genetic factors: Variation in phase II conjugating enzymes (UGT and SULT) and in drug-metabolizing enzymes affects how quickly any absorbed naringenin is cleared, which could influence the small chance of systemic effects; there is no evidence this is clinically important for topical use.

  • Baseline biomarker levels: People already taking medications with narrow safety margins that depend on CYP3A4 clearance would be more vulnerable if systemic absorption were higher than expected.

  • Sex-based differences: Because naringenin has weak estrogen-like activity, women — particularly those with hormone-sensitive conditions — warrant more caution regarding the theoretical hormonal risk than men.

  • Pre-existing health conditions: Eczema, psoriasis, or any broken scalp skin increases both irritation and absorption; hormone-sensitive cancers raise the theoretical concern about phytoestrogen exposure.

  • Age-related considerations: Older adults tend to have thinner, more permeable skin and a higher medication burden, modestly increasing both irritation risk and the potential for systemic exposure at the older end of the target range.

Key Interactions & Contraindications

  • Prescription drug interactions (topical): Topical minoxidil is the main relevant co-treatment; the interaction is additive and beneficial rather than harmful (caution: none; monitor scalp tolerance). Topical retinoids (tretinoin, adapalene) increase skin permeability and could raise irritation and absorption — caution, separate application times.

  • Prescription drug interactions (systemic, theoretical): Absorbed naringenin can inhibit CYP3A4 and related enzymes, which could raise levels of CYP3A4-dependent drugs (statins such as simvastatin, calcium-channel blockers such as amlodipine, certain immunosuppressants such as tacrolimus). Severity: caution and theoretical only for scalp application; consequence: increased drug exposure and side effects; mitigation: avoid combining with concurrent high-dose oral naringenin or grapefruit if taking these medicines.

  • Over-the-counter medication interactions: Alcohol-based OTC scalp products and exfoliating agents (salicylic acid) can compound irritation — caution, avoid stacking multiple irritants on the same day.

  • Supplement interactions: Oral naringenin supplements and grapefruit extract add to the systemic (grapefruit-effect) concern; other antioxidant flavonoids (quercetin) provide overlapping, not clearly additive, benefit.

  • Additive (beneficial) combinations: Minoxidil (demonstrated additive hair effect in the animal study) and other topical follicle stimulants (caffeine, rosemary oil) may complement naringenin, though combinations are untested in humans.

  • Other intervention interactions: Microneedling before application markedly increases skin penetration and therefore both potential benefit and irritation — treat as a caution, not a routine pairing.

  • Populations who should avoid it: Pregnant or breastfeeding individuals (no safety data; phytoestrogen activity), people with active hormone-sensitive cancers (theoretical estrogen-like exposure), those with a known citrus-flavonoid allergy (absolute avoidance), and anyone with broken, infected, or actively inflamed scalp skin (avoid until healed). There are no validated numeric thresholds; the practical classification is avoid with any open scalp lesion, avoid during pregnancy and lactation, and avoid with a documented flavonoid allergy.

Risk Mitigation Strategies

  • Patch test before scalp use: Apply a small amount to the inner forearm for 48 hours and check for redness or itching before using on the scalp; this screens for the contact allergy and irritation risks at minimal exposure.

  • Start at a low concentration: Begin with a low-strength preparation (the animal study used 0.5%) once daily and increase only if well tolerated, limiting the irritation risk while gauging skin response over 1–2 weeks.

  • Apply only to intact skin: Avoid broken, sunburned, or inflamed scalp; this prevents the higher absorption and irritation that damaged skin causes, reducing both local and any systemic risk.

  • Separate from other actives: Space naringenin at least several hours from retinoids, exfoliating acids, or alcohol-heavy products to avoid additive irritation.

  • Limit total exposure: Keep application to the affected scalp area rather than large skin surfaces, minimizing the already-small chance of the systemic phytoestrogen and drug-interaction effects.

  • Review concurrent medications and supplements: Anyone on CYP3A4-dependent drugs should avoid pairing topical use with high-dose oral naringenin or grapefruit, mitigating the theoretical drug-metabolism interaction.

  • Stop if dermatitis develops: Discontinue at the first sign of persistent redness, swelling, or rash to prevent progression to established contact dermatitis.

Therapeutic Protocol

  • No standardized regimen exists: Because naringenin is untested in humans for hair, there is no established dose, concentration, or schedule; everything below is extrapolated and should be read as experimental.

  • Concentration and formulation: The one animal study used a 0.5% topical preparation; compounded solutions or gels in ethanol, propylene glycol, or a nanoemulsion are used to help the poorly water-soluble compound penetrate the skin.

  • Frequency and dosing pattern: By analogy to minoxidil, once- or twice-daily application to the dry scalp is the pragmatic pattern; because the compound’s local action is brief, split (twice-daily) dosing is the more logical choice than a single daily dose.

  • Best time of day: No circadian data exist; consistent morning and evening timing is used simply to keep exposure even, with the scalp left to dry before covering.

  • Half-life consideration: Any absorbed naringenin has a short systemic half-life (a few hours), reinforcing frequent local re-application rather than reliance on a lasting reservoir.

  • Competing approaches: Three approaches are described without one being the default — naringenin as a stand-alone experimental topical, naringenin as an add-on to 5% minoxidil (the combination that performed best in the animal study), and naringenin paired with microneedling to boost delivery. Each has only preclinical or theoretical support.

  • Who popularized it: No clinic or named practitioner has established a protocol; the primary source is an academic group (University of Kufa) that ran the animal study, not a commercial or clinical programme.

  • Genetic considerations: Individuals whose hair loss is strongly androgen-driven (governed by androgen-receptor and 5α-reductase variants) may be better served by protocols that include a hormonal agent, since naringenin does not strongly target that pathway.

  • Sex-based considerations: Dosing has not been differentiated by sex; women with hormone-sensitive conditions may prefer more conservative use given the weak estrogen-like activity.

  • Age-related considerations: Older adults with thinner skin may need lower concentrations to limit irritation and absorption.

  • Baseline biomarkers: Correcting low iron stores, low vitamin D, or thyroid abnormalities before or alongside use gives any topical a fairer chance to work.

  • Pre-existing conditions: Active scalp inflammation or dermatitis should be treated first, as it alters both tolerability and absorption.

Discontinuation & Cycling

  • Likely continuous use: As with other topical hair treatments, any benefit almost certainly depends on ongoing application; hair gains from follicle-stimulating topicals typically reverse within months of stopping, so naringenin is best thought of as a maintenance approach rather than a cure.

  • No known withdrawal effects: There is no evidence of a withdrawal syndrome; the expected consequence of stopping is a gradual return toward the untreated baseline as any newly supported follicles cycle out.

  • No tapering required: Because there is no dependence or rebound documented, stopping abruptly is not known to cause harm and no tapering schedule is needed.

  • Cycling not established: No evidence supports cycling on and off to maintain effect; continuous use is the only pattern with any (indirect) rationale.

Sourcing and Quality

  • Raw material form: Naringenin is sold mainly as a bulk powder (aglycone), derived from citrus sources or produced synthetically; finished topical products are rare, so most use is via compounding or do-it-yourself preparation.

  • Purity to look for: Seek material specified at ≥98% purity by high-performance liquid chromatography (HPLC, a lab method that separates and quantifies compounds) with a batch certificate of analysis (COA).

  • Third-party testing: Because naringenin is often sold as a research chemical or bulk supplement rather than a regulated drug, independent third-party testing for identity, purity, heavy metals, and solvent residues is important; prefer suppliers who publish COAs.

  • Formulation stability: Naringenin degrades with light and at high pH, so opaque packaging and a suitably acidic, well-designed vehicle matter more than for a stable drug; a reputable compounding pharmacy is better placed to ensure this than an ad-hoc mixture.

  • Reputable sources: Compounding pharmacies (for a properly formulated topical) and established bulk suppliers with published analytical certificates are the most reliable options; avoid unlabelled powders without documentation.

Practical Considerations

  • Time to effect: Hair grows slowly, so even if naringenin works, visible change would take at least one full hair cycle — on the order of 3–6 months of consistent use — before any judgement is possible; the animal study ran over weeks, not the years relevant to human hair.

  • Common pitfalls: Expecting oral naringenin or grapefruit intake to help hair (there is no evidence for a systemic route to the scalp), using an unstable homemade preparation that degrades, applying too little too infrequently, and abandoning it before a full cycle has elapsed.

  • Regulatory status: Naringenin is not approved by the U.S. Food and Drug Administration (FDA) for hair loss or any condition; it is sold as a dietary ingredient, cosmetic ingredient, or research chemical, and any hair use is experimental and off-label in the broad sense.

  • Cost and accessibility: The raw compound is inexpensive, but the need to compound a stable topical (and the scarcity of ready-made products) is the real access barrier rather than price.

  • Realistic expectations: Because the entire case rests on animal and laboratory data, use should be approached as a personal experiment with an uncertain payoff, not as an established treatment.

Interaction with Foundational Habits

  • Sleep: The interaction is indirect. Poor sleep raises stress hormones that can worsen shedding; naringenin does not act on sleep, but its potential benefit is easier to detect against a background of adequate rest. No timing relative to dosing is relevant.

  • Nutrition: The interaction is indirect and potentiating. Adequate protein, iron, zinc, and vitamin D are prerequisites for hair growth, so correcting deficiencies supports any topical effect; dietary naringenin from citrus is a separate matter and, in large amounts (grapefruit), carries its own drug-interaction consideration rather than a hair benefit.

  • Exercise: The interaction is indirect. Regular exercise improves scalp perfusion and lowers systemic inflammation, complementing naringenin’s proposed blood-vessel and anti-inflammatory actions; there is no need to time application around workouts, though applying to a clean, dry scalp after showering is practical.

  • Stress management: The interaction is indirect and potentiating. Chronic stress raises cortisol and oxidative stress, both linked to hair shedding; naringenin’s antioxidant action theoretically counters part of this, so stress-reduction practices and the compound target overlapping problems from different directions.

Monitoring Protocol & Defining Success

Before starting, a proactive user should document a clear baseline and rule out common treatable causes of hair loss, so that any change can be attributed and reversible deficiencies are corrected. This means standardized scalp photographs, a hair-pull test, and ideally trichoscopy (magnified scalp imaging) to record hair density and follicle diameter, plus the blood tests below.

Ongoing monitoring should follow the slow pace of hair biology: repeat standardized photographs every 8–12 weeks and repeat trichoscopy and the relevant blood tests every 3–6 months, since meaningful change cannot appear faster than the hair cycle allows.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin 40–70 ng/mL Low iron stores independently impair hair growth Acute-phase reactant — pair with C-reactive protein (CRP, a general inflammation marker); conventional “normal” starts far lower (~15–30 ng/mL); no fasting required
Vitamin D (25-hydroxyvitamin D) 40–60 ng/mL Deficiency is associated with hair loss and poor follicle cycling Conventional sufficiency is set lower (≥20–30 ng/mL); no fasting required; best paired with calcium status if supplementing
Thyroid-stimulating hormone (TSH) 0.5–2.5 mIU/L Thyroid dysfunction is a common, reversible cause of shedding Conventional range extends to ~4.5 mIU/L; draw in the morning, fasting preferred; pair with free thyroxine if abnormal

Qualitative markers to track alongside the labs and photographs:

  • Reduced daily shedding (fewer hairs on the pillow, in the shower, or on the brush)
  • Appearance of fine new (vellus) regrowth along the hairline or part
  • Improved perceived hair thickness, coverage, and quality
  • Scalp comfort — absence of irritation, itching, or redness from the product

Emerging Research

  • No hair-specific human trials are under way: A search of ClinicalTrials.gov found no registered trial of topical naringenin for hair loss or regrowth. The only currently recruiting human naringenin trial studies a different use — NCT06612762 (Naringenin Supplementation in Bone Fracture Patients, an oral-supplementation study enrolling about 70 participants) — underscoring that human work on naringenin is advancing outside dermatology.

  • Human safety and pharmacokinetics groundwork: An earlier completed early-phase study, NCT03582553 (Safety and Pharmacokinetics of an Extract of Naringenin, about 18 participants), provides some human exposure data that a future topical programme could build on.

  • Anchor preclinical study to replicate: The mouse experiment by Khayoon et al., 2023 is the finding most in need of human replication; a controlled trial in people with pattern hair loss, ideally testing naringenin both alone and added to minoxidil, would most strengthen the case.

  • Pigmentation direction: The pigment-focused review by Wei et al., 2025 points to hair-colour outcomes (greying reversal) as a distinct, largely unexplored research avenue that could either add to or diverge from the regrowth story.

  • Mechanistic mapping: The plant-extract review by Choi et al., 2024 frames the growth-factor and signalling targets that future studies would need to confirm naringenin actually engages in human follicles.

  • What could weaken the case: Failure to reproduce the animal effect in humans, instability or poor skin penetration of practical formulations, or evidence that meaningful systemic absorption carries hormonal or drug-interaction risk would each undercut current enthusiasm; these are the outcomes a careful reader should watch for as much as positive results.

Conclusion

Naringenin is a natural compound from citrus fruits that some researchers are now applying directly to the scalp in the hope of slowing hair loss and encouraging regrowth. The interest is understandable: in the laboratory and in a single animal study it protects cells from stress-related damage, calms inflammation, and raises a signal that helps build the tiny blood vessels feeding hair roots — the same kinds of effects thought to underlie standard hair treatments. In that animal work it increased hair growth on its own and worked even better alongside the usual topical treatment.

The honest bottom line is that the evidence is early and thin. Everything known comes from cells and mice; no human has been tested for this use, so whether it regrows hair in people, and by how much, is genuinely unknown. The likely downsides are modest — mainly skin irritation — with only theoretical concerns about hormone-like activity or absorbed amounts affecting other medicines. The small body of work is academic rather than industry-driven, which limits commercial bias but also means little momentum behind larger studies. For someone weighing it, naringenin for hair is best seen as a plausible but unproven experiment, promising enough to follow yet far from established.

Top - Benefits - Risks - Protocol